FDA Investigator Laressa R Gray
Laressa R Gray has inspections in 1 countries as of 24 Oct 2023. Laressa R Gray has collaborated with a combined 1197 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
36
Last Inspection Date:
24 Oct 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America
Co-Investigator(s):
Abby Lmozeke Baker,
Albert F Peacock, PhD,
Andria L Kuhlman,
Anthony D Peterson,
Barbara D Wright,
Barbara G Peoples,
Brian S Lynch,
Camilla S Smith,
Carl A Huffman, III,
Carolyn A Pinney,
Cheryl L Watson,
Christopher J Adams,
Cody D Rickman,
Craig T Rybus,
Cynthia L Medlin,
Danielle M Maddox,
David R Heiar,
Donna D Gallien, MPH,
Eddie J Rigsby,
Elizabeth D Battles,
Elizabeth D Connell,
Emily E Smith,
Erika M Wilkerson,
Fabian Nchaparro Rodriguez,
George J Flynn,
Jaime E Perry,
Jason D Abel,
Jean A Peeples,
Jennifer L Jager,
Jennifer L Sheehan,
Juanelma H Palmer,
Karen Gale Sego,
Karen M Cooper,
Kenneth K Merritt,
Kenneth R Merritt,
Kimberly Cdelk Brooks,
Kip J Hanks,
Konsuela Y Glass,
Lacey J Chessor,
Laura E Garcia,
Laura L Staples,
Lawrence A Butler,
LCDR Randall L Morris,
Leena Thomas,
Lillie M Young,
Lisa R Jennings,
Marianne Allen,
Mary T Carden,
Melanie L Drayton,
Merelynn Rhoten,
Michael J Schibi,
Michael T Nehring,
Monica Y Yu,
Myla T Collins,
Nancy L Neiger,
Nisha C Patel,
Paula J Perry,
Randy L Clarida,
Robert E Hultman,
Robert M Tillman,
Robert W Hudson,
Samantha J Pinizzotto, D V M,
Tammara D Perry,
Thomas R Stanley,
Thomas W Nojek,
Tiana M Mckinley,
Whitney M White
Laressa R Gray's Documents
Publish Date | Document Type | Title |
---|---|---|
March, 2022 | FDA 483 | Octapharma Plasma Inc - Form 483, 2022-03-04 |
August, 2022 | FDA 483 | American Red Cross Blood Services Tennessee Valley Region - Form 483, 2022-08-31 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more